Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa
| Autor: | Tae Eun Park, Eric R Ocheretyaner |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Methicillin-Resistant Staphylococcus aureus 0301 basic medicine Microbiology (medical) 030106 microbiology medicine.disease_cause Microbiology 03 medical and health sciences chemistry.chemical_compound Virology Drug Resistance Bacterial Humans Medicine Pseudomonas Infections business.industry Pseudomonas aeruginosa Bacterial Infections Skin Diseases Bacterial Staphylococcal Infections Antimicrobial Methicillin-resistant Staphylococcus aureus Anti-Bacterial Agents Infectious Diseases chemistry Delafloxacin business Fluoroquinolones |
| Zdroj: | Expert Review of Anti-infective Therapy. 16:523-530 |
| ISSN: | 1744-8336 1478-7210 |
| Popis: | The resistance to current antimicrobial agents, including fluoroquinolones, has continued to grow among various pathogens indicating a need for new antimicrobials to combat multi-drug resistant (MDR) organisms. In June 2017, delafloxacin received approval by the US Food and Drug Administration for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) in adults caused by designated susceptible bacteria. Areas covered: This review describes the pharmacology, pharmacodynamics, pharmacokinetics, product information, efficacy, and safety of delafloxacin. Expert commentary: Delafloxacin is a novel oral and intravenous fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, offering a new option for the treatment of ABSSSI and potentially for complicated urinary tract infections and severe community-acquired bacterial pneumonia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|